ru-66647 and Cross-Infection

ru-66647 has been researched along with Cross-Infection* in 2 studies

Reviews

1 review(s) available for ru-66647 and Cross-Infection

ArticleYear
New antibiotic agents: problems and prospects.
    Surgical infections, 2005, Volume: 6 Suppl 2

    Surgical site infections are the third most common healthcare-associated infection, often leading to prolonged hospital stay and excessive expenditures. Management of these infections has become more challenging due to rising rates of multi-drug-resistant organisms and few new antibiotic options.. This paper reviews the literature, summarizes the epidemiology of surgical site infections and the threat of antibiotic-resistant bacteria, and provides an insight into new treatment options for this condition.. Patients with surgical site infections are at greater risk of acquiring healthcare-associated antibiotic-resistant pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE) sp., and extended-spectrum beta-lactamase-(ESBL)-producing Escherichia coli and Klebsiella pneumoniae. Multi-drug-resistant Pseudomonas aeruginosa and Bacteroides fragilis are also a growing problem. Several useful drugs have recently become available for the management of serious, gram-positive infections (e.g., daptomycin, linezolid, telithromycin). Tigecycline, the first-in-class glycylcycline, has broad-spectrum in vitro activity, including against MRSA, VRE, resistant enteric gram-negative bacilli (e.g., Acinetobacter sp.), "atypical" pathogens, and anaerobes. Phase 3 clinical trials suggest that tigecycline will be an excellent option for antibiotic monotherapy for complicated skin and soft tissue infections (cSSSI) and intra-abdominal infections. Oritavancin and dalbavacin, two novel glycopeptide antibiotics that are also in late-stage clinical development, appear that they, too, will be useful for cSSSI due to resistant, gram-positive bacteria.. Multi-drug-resistant pathogens are threatening the success of available antibiotic therapy. Many new options are useful for infections due to multi-drug-resistant, gram-positive bacteria. Tigecycline is a promising new agent that provides coverage against a broad spectrum of gram-positive and gram-negative, aerobic, facultative, and anaerobic strains, including resistant isolates, and may make broad-spectrum, single-agent therapy possible.

    Topics: Acetamides; Acinetobacter; Anti-Bacterial Agents; Cross Infection; Daptomycin; Drug Resistance, Multiple, Bacterial; Humans; Ketolides; Linezolid; Methicillin-Resistant Staphylococcus aureus; Minocycline; Oxazolidinones; Pseudomonas aeruginosa; Surgical Wound Infection; Tigecycline; Vancomycin Resistance

2005

Other Studies

1 other study(ies) available for ru-66647 and Cross-Infection

ArticleYear
Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:3

    The rates of resistance to erythromycin and clindamycin among Streptococcus agalactiae strains isolated in our hospital increased from 4.2 and 0.8% in 1993 to 17.4 and 12.1%, respectively, in 2001. Erythromycin resistance was mainly due to the presence of an Erm(B) methylase, while the M phenotype was detected in 3.8% of the strains. Telithromycin was very active against erythromycin-resistant strains, irrespective of their mechanisms of macrolide resistance.

    Topics: Anti-Bacterial Agents; Clindamycin; Cross Infection; Drug Resistance, Bacterial; Erythromycin; Humans; Infant, Newborn; Ketolides; Macrolides; Microbial Sensitivity Tests; Spain; Streptococcal Infections; Streptococcus agalactiae; Tetracycline Resistance

2003